Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOBEC3A | P31941 | 1/20 | 0.73 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | MGLL | Q99685 | 2/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NAMPT | P43490 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MC4R | P32245 | 1/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.35 |
| ▸ | MC3R | P41968 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL569917 | 0.84 | APOBEC3A (1.00) | APOBEC3AAPOBEC3GHTR2AHTR2CGFER | |
| SCHEMBL13995847 | 0.83 | APOBEC3A (0.73) | APOBEC3AAPOBEC3GHTR2AHTR2CGFER | |
| SCHEMBL17321385 | 0.79 | APOBEC3A (0.67) | APOBEC3AAPOBEC3GHTR2AHTR2CGFER | |
| SCHEMBL17883352 | 0.79 | APOBEC3A (0.67) | APOBEC3AAPOBEC3GHTR2AHTR2CGFER | |
| SCHEMBL4250069 | 0.79 | APOBEC3A (0.67) | APOBEC3AAPOBEC3GHTR2AHTR2CGFER | |
| SCHEMBL4312244 | 0.79 | APOBEC3A (0.67) | APOBEC3AAPOBEC3GHTR2AHTR2CGFER | |
| SCHEMBL7048077 | 0.78 | APOBEC3A (0.65) | APOBEC3AAPOBEC3GHTR2AHTR2CGFER | |
| SCHEMBL4794765 | 0.75 | APOBEC3A (0.61) | APOBEC3AAPOBEC3GHTR2AHTR2CGFER | |
| SCHEMBL4428625 | 0.75 | APOBEC3A (0.61) | APOBEC3AAPOBEC3GHTR2AHTR2CGFER | |
| SCHEMBL17460372 | 0.75 | APOBEC3A (0.61) | APOBEC3AAPOBEC3GHTR2AHTR2CGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4090426-A1 | SUBSTITUTED PYRAZOLO-PYRIMIDINES AND USES THEREOF | Verge Analytics, Inc. (US) | 2022-11-23 | — | — | EP | claimed |
| CN-115108972-A | Synthetic method of 2-methyl-3-fluoro-5-bromopyridine | 北京迪泰医药科技有限公司 | 2022-09-27 | — | — | CN | claimed |
| EP-4727541-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2025198486-A1 | PROCESS FOR PREPARING A PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUND | BIAL – R&D Investments, S.A. (PT) | 2025-09-25 | — | — | WO | disclosed |
| CN-119899188-A | METTL3 inhibitors | 杭州邦顺制药有限公司 | 2025-04-29 | — | — | CN | disclosed |
| EP-4540242-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119654318-A | Compounds and pharmaceutical compositions for degrading SWI/SNF-associated matrix-associated actin-dependent chromatin subfamily A modulators | 普莱克斯姆公司 | 2025-03-18 | — | — | CN | disclosed |
| WO-2024259336-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2024-12-19 | — | — | WO | disclosed |
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-02-22 | — | — | US | disclosed |
| WO-2023244806-A1 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THAT DEGRADE SWI/SNF-RELATED MATRIX-ASSOCIATED ACTIN-DEPENDENT REGULATOR OF CHROMATIN SUBFAMILY A | Plexium, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| EP-4271664-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-11-08 | — | — | EP | disclosed |
| WO-2020264499-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-30 | — | — | WO | disclosed |
| EP-3452045-A1 | METHODS OF TREATMENT AND COMBINATION THERAPIES USING GCASE ACTIVATOR HETEROBICYCLIC AND RELATED COMPOUNDS | Lysosomal Therapeutics Inc. (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-3440080-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Lysosomal Therapeutics Inc. (US) | 2019-02-13 | — | — | EP | disclosed |
| WO-2017192841-A1 | METHODS OF TREATMENT AND COMBINATION THERAPIES USING GCASE ACTIVATOR HETEROBICYCLIC AND RELATED COMPOUNDS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-11-09 | — | — | WO | disclosed |
| WO-2017176960-A1 | PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2017-10-12 | — | — | WO | disclosed |
| EP-3215511-A1 | SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | Lysosomal Therapeutics Inc. (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016073895-A1 | SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS | LYSOSOMAL THERAPEUTICS INC. (US) | 2016-05-12 | — | — | WO | disclosed |
| EP-2721029-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | Merck Sharp & Dohme Corp. (US) | 2014-04-23 | — | — | EP | disclosed |
| WO-2012174199-A1 | IMIDAZOPYRIDIN-2-ONE DERIVATIVES | MERCK SHARP & DOHME CORP. (US) | 2012-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059674-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | APOBEC3A 219/4885APOBEC3G 151/4885HTR2A 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.